ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib
- Edward S. Kim
- , Fabrice Barlesi
- , Tony Mok
- , Myung Ju Ahn
- , Junwu Shen
- , Pingkuan Zhang
- , Sai Hong Ignatius Ou
- Levine Cancer Institute
- Aix-Marseille University
- Gustave Roussy
- Chinese University of Hong Kong
- Sungkyunkwan University
- Takeda Pharmaceutical Company Limited
- University of California at Irvine
Research output: Contribution to journal › Article › peer-review
15
Link opens in a new tab
Scopus
citations